284 related articles for article (PubMed ID: 23425609)
1. Once weekly exenatide: efficacy, tolerability and place in therapy.
Wysham C; Grimm M; Chen S
Diabetes Obes Metab; 2013 Oct; 15(10):871-81. PubMed ID: 23425609
[TBL] [Abstract][Full Text] [Related]
2. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.
Ridge T; Moretto T; MacConell L; Pencek R; Han J; Schulteis C; Porter L
Diabetes Obes Metab; 2012 Dec; 14(12):1097-103. PubMed ID: 22734440
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
4. Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
Ryan GJ; Moniri NH; Smiley DD
Am J Health Syst Pharm; 2013 Jul; 70(13):1123-31. PubMed ID: 23784159
[TBL] [Abstract][Full Text] [Related]
5. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.
Scott DA; Boye KS; Timlin L; Clark JF; Best JH
Diabetes Obes Metab; 2013 Mar; 15(3):213-23. PubMed ID: 22958381
[TBL] [Abstract][Full Text] [Related]
6. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.
Madsbad S; Kielgast U; Asmar M; Deacon CF; Torekov SS; Holst JJ
Diabetes Obes Metab; 2011 May; 13(5):394-407. PubMed ID: 21208359
[TBL] [Abstract][Full Text] [Related]
7. [Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR)].
Scheen AJ
Rev Med Liege; 2014 Apr; 69(4):214-9. PubMed ID: 24923102
[TBL] [Abstract][Full Text] [Related]
8. [Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
Lecube A; Bueno M; Suárez X
Med Clin (Barc); 2014 Sep; 143 Suppl 2():23-7. PubMed ID: 25437462
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
Owens DR; Monnier L; Bolli GB
Diabetes Metab; 2013 Dec; 39(6):485-96. PubMed ID: 24156868
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
[TBL] [Abstract][Full Text] [Related]
11. Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies.
Stonehouse A; Walsh B; Cuddihy R
Diabetes Technol Ther; 2011 Oct; 13(10):1063-9. PubMed ID: 21732798
[TBL] [Abstract][Full Text] [Related]
12. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
DeYoung MB; MacConell L; Sarin V; Trautmann M; Herbert P
Diabetes Technol Ther; 2011 Nov; 13(11):1145-54. PubMed ID: 21751887
[TBL] [Abstract][Full Text] [Related]
13. A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.
Henry RR; Logan D; Alessi T; Baron MA
Clin Ther; 2013 May; 35(5):634-645.e1. PubMed ID: 23578605
[TBL] [Abstract][Full Text] [Related]
14. Is insulin the most effective injectable antihyperglycaemic therapy?
Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M
Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312
[TBL] [Abstract][Full Text] [Related]
15. Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.
McCormack PL
Drugs; 2014 Mar; 74(3):325-51. PubMed ID: 24435322
[TBL] [Abstract][Full Text] [Related]
16. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
Diamant M; Van Gaal L; Guerci B; Stranks S; Han J; Malloy J; Boardman MK; Trautmann ME
Lancet Diabetes Endocrinol; 2014 Jun; 2(6):464-73. PubMed ID: 24731672
[TBL] [Abstract][Full Text] [Related]
17. Evolution of exenatide as a diabetes therapeutic.
Bhavsar S; Mudaliar S; Cherrington A
Curr Diabetes Rev; 2013 Mar; 9(2):161-93. PubMed ID: 23256660
[TBL] [Abstract][Full Text] [Related]
18. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
Wysham C; Bergenstal R; Malloy J; Yan P; Walsh B; Malone J; Taylor K
Diabet Med; 2011 Jun; 28(6):705-14. PubMed ID: 21434995
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes.
Grossman SS
Adv Ther; 2014 Mar; 31(3):247-63. PubMed ID: 24535624
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.
Davies M; Speight J
Diabetes Obes Metab; 2012 Oct; 14(10):882-92. PubMed ID: 22420869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
